These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14744791)

  • 21. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
    Bhatla D; Gerbing RB; Alonzo TA; Conner H; Ross JA; Meshinchi S; Zhai X; Zamzow T; Mehta PA; Geiger H; Perentesis J; Davies SM
    Br J Haematol; 2009 Feb; 144(3):388-94. PubMed ID: 19036079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
    Tanaka M; Yoshida S
    Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3'-amino-2',3'-dideoxycytidine and cytosine arabinoside.
    Mancini WR
    Cancer Chemother Pharmacol; 1992; 30(2):139-44. PubMed ID: 1318170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
    Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA
    Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
    Reuter C; Schleyer E; Rolf C; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1997 Apr; 11(4):561-71. PubMed ID: 9096697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
    Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity.
    Tang J; Xie X; Zhang X; Qiao X; Jiang S; Shi W; Shao Y; Zhou X
    Front Biosci (Landmark Ed); 2012 Jan; 17(2):569-74. PubMed ID: 22201761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
    Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
    Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
    Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
    Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.
    Cabelof DC; Patel HV; Chen Q; van Remmen H; Matherly LH; Ge Y; Taub JW
    Blood; 2009 Sep; 114(13):2753-63. PubMed ID: 19633202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down syndrome, drug metabolism and chromosome 21.
    Taub JW; Ge Y
    Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
    Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
    Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
    Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
    Grant S; Turner A; Nelms P; Yanovich S
    Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.
    Fanciullino R; Farnault L; Donnette M; Imbs DC; Roche C; Venton G; Berda-Haddad Y; Ivanov V; Ciccolini J; Ouafik L; Lacarelle B; Costello R
    Blood Adv; 2018 Mar; 2(5):462-469. PubMed ID: 29490977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview.
    Rustum YM; Raymakers RA
    Pharmacol Ther; 1992 Dec; 56(3):307-21. PubMed ID: 1301593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.